FluoGuide develops FG001, an imaging agent that makes cancer cells fluorescent during surgery, enhancing the precision of tumor removal. This technology aims to reduce cancer recurrence and surgical complications, ultimately lowering healthcare costs and improving patient outcomes.
Funding
$25.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Surgeons often struggle to distinguish between cancerous and healthy tissue during surgery, especially with aggressive cancers, leading to incomplete tumor removal and increased risk of recurrence. Current methods lack the precision needed to ensure all cancer cells are removed, potentially resulting in additional surgeries and complications.
Solution
FluoGuide develops FG001, an innovative imaging agent that makes cancer cells fluoresce during surgery, allowing surgeons to more accurately identify and remove tumors. By illuminating cancerous tissue, FG001 enhances surgical precision, potentially reducing the likelihood of cancer recurrence and minimizing surgical complications. This technology aims to improve patient outcomes by ensuring more complete tumor removal in the initial surgery, thereby lowering the need for readmissions and subsequent treatments. FG001 is currently in Phase II clinical trials for aggressive brain cancer, head and neck cancer, and lung cancer.
Target Audience
The primary target audience includes surgeons and hospitals specializing in cancer treatment, particularly those focused on aggressive brain, head and neck, and lung cancers.
Features
- Makes cancer cells fluorescent during surgery for enhanced visualization.
- Applicable to approximately 80% of solid cancers.
- Designed to improve surgical precision and reduce cancer recurrence.
- Currently in Phase II clinical trials for aggressive brain cancer (high-grade glioma), head and neck cancer, and lung cancer.